Idelalisib + Nab-paclitaxel + mFOLFOX6
Phase 1TerminatedDevelopment Stage
Previously Untreated Pancreatic Ductal Adenocarcinoma
Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Jul 30, 2015 → Apr 27, 2016
About Idelalisib + Nab-paclitaxel + mFOLFOX6
Idelalisib + Nab-paclitaxel + mFOLFOX6 is a phase 1 stage product being developed by Gilead Sciences for Previously Untreated Pancreatic Ductal Adenocarcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02468557. Target conditions include Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
1 of 3 similar drugs in Previously Untreated Pancreatic Ductal Adenocarcinoma were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02468557 | Phase 1 | Terminated |
Competing Products
8 competing products in Previously Untreated Pancreatic Ductal Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811 | Jiangsu Hengrui Medicine | Phase 3 | 44 |
| AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim | AstraZeneca | Phase 2 | 27 |
| AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin | AstraZeneca | Phase 2 | 27 |
| UFOX + Cetuximab + FOLFOX4 + Cetuximab | Merck | Phase 2 | 35 |
| Bosutinib | Pfizer | Approved | 35 |
| CRS-207 + CRS-207 + nivolumab + GVAX + CY | Bristol Myers Squibb | Phase 2 | 35 |
| Lenalidomide + Dexamethasone + Elotuzumab | Bristol Myers Squibb | Phase 3 | 32 |
| Oxaliplatin | Sanofi | Phase 2 | 31 |